<bill session="115" type="h" number="7251" updated="2019-05-29T12:29:29Z">
  <state datetime="2018-12-11">REFERRED</state>
  <status>
    <introduced datetime="2018-12-11"/>
  </status>
  <introduced datetime="2018-12-11"/>
  <titles>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.</title>
    <title type="short" as="introduced">Hatch-Waxman Integrity Act of 2018</title>
    <title type="short" as="introduced">Hatch-Waxman Integrity Act of 2018</title>
    <title type="display">Hatch-Waxman Integrity Act of 2018</title>
  </titles>
  <sponsor bioguide_id="F000461"/>
  <cosponsors/>
  <actions>
    <action datetime="2018-12-11">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-12-11" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2018-12-11">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSBA" name="House Financial Services" activity="Referral"/>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="s" session="115" relation="identical" number="3738"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative remedies"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Fraud offenses and financial crimes"/>
    <term name="Intellectual property"/>
    <term name="Licensing and registrations"/>
    <term name="Prescription drugs"/>
    <term name="Securities"/>
  </subjects>
  <amendments/>
  <summary date="2018-12-11T05:00:00Z" status="Introduced in House">Hatch-Waxman Integrity Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.</summary>
  <committee-reports/>
</bill>
